Z79.811
Long term (current) use of aromatase inhibitors
Clinical Classification Guidelines
Inclusion Terms
- Long term (current) use of anastrozole (Arimidex)
- Long term (current) use of exemestane (Aromasin)
- Long term (current) use of letrozole (Femara)
Medical Intelligence & Overview
Aromatase inhibitors are medications commonly used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. The ICD-10 code Z79.811 refers to the long-term or ongoing use of these medications, including anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). This classification helps healthcare providers track and manage patients who are on extended therapy to reduce cancer recurrence risk.
Causes & Symptoms
Clinical Causes: History of hormone receptor-positive breast cancer requiring ongoing hormone suppression therapy. As part of adjuvant therapy post-cancer surgery to decrease the risk of cancer returning. Management of advanced or metastatic breast cancer where continued hormone suppression is necessary. Physician-directed strategy to maintain remission or prevent recurrence during long-term treatment. Patient-specific considerations such as menopausal status or previous response to treatment.
Key Symptoms: Hormonal-related side effects which may include hot flashes or night sweats. Musculoskeletal discomfort such as joint pain or stiffness. Reduced bone mineral density leading to osteoporosis risks. Mood changes or fatigue. Potential cardiovascular effects like increased cholesterol levels. Other side effects including nausea or changes in weight and appetite.
Diagnostic & Treatment
Diagnosis Path: Long-term use of aromatase inhibitors is primarily documented through medical history and prescription records. Clinicians often monitor patient response and side effects during follow-up visits, utilizing bone density scans, blood tests for lipid profiles, and assessments of symptoms to manage ongoing therapy effectively.
Treatment Protocols: While this article focuses on describing the code, management of side effects and ongoing health monitoring are crucial components of long-term aromatase inhibitor therapy. Patients may undergo regular bone density screening, blood tests, and symptom assessments. Adjustments to treatment plans, including supplemental therapies like bisphosphonates or lifestyle modifications, can help mitigate adverse effects.
Clinical Advice & FAQs
Billing Guidance
Is Z79.811 a billable ICD-10 code?
Yes, Z79.811 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z79.811?
Clinical documentation must specify the nature of Long term (current) use of aromatase inhibitors and any associated comorbidities for accurate reporting.
Cite this Clinical Reference